Annals of neurology
-
Annals of neurology · Sep 2010
Multicenter Study Clinical TrialAssessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab-treated multiple sclerosis (MS) patients to predict the risk of progressive multifocal leukoencephalopathy (PML). ⋯ Measuring JCV DNA in blood or urine with currently available methods is unlikely to be useful for predicting PML risk in natalizumab-treated MS patients.